Business
Astrana Health operates technology-enabled physician networks and risk-bearing care platforms.
Astrana Health grew revenue, remained profitable, generated positive free cash flow at a 2.5% operating margin. Revenue rose rapidly, but net income, margins and free cash flow remained modest.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 56.4%OK
- Profitability — Net income declined 47.9% to $22.487M from $43.149MWatch
- Cash flow — Free cash flow grew 136.6% to $104.491M from $44.167MOK
- Margins — Operating margin contracted 192 bps to 2.47%Watch
- Accounting — Revenue rose rapidly, but net income, margins and free cash flow remained modestNote
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2025, as Astrana Health, Inc. reports it. History and quarterly detail are in the app.
- Care Partners$3.0B
- Care Delivery$250.7M
- Care Enablement$246.7M
Leadership changes
From Astrana Health, Inc.'s own filings, the day they're filed.
- John Vong · President · appointmenteff. 2026-07-01
- Dinesh Kumar · Chief Medical Officer · departureeff. 2026-06-01
- Glenn W. Sobotka · Chief Accounting Officer · appointmenteff. 2025-03-26
Latest filings
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-13
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Astrana Health, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.